Inhibrx Biosciences (INBX) Accumulated Depreciation & Amortization (2023 - 2025)
Inhibrx Biosciences (INBX) has disclosed Accumulated Depreciation & Amortization for 3 consecutive years, with $582000.0 as the latest value for Q3 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization fell 63.53% to $582000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $582000.0, a 63.53% decrease, with the full-year FY2024 number at $2.3 million, up 91.86% from a year prior.
- Accumulated Depreciation & Amortization was $582000.0 for Q3 2025 at Inhibrx Biosciences, down from $662000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $2.3 million in Q4 2024 to a low of $295000.0 in Q2 2023.
- A 3-year average of $842500.0 and a median of $622000.0 in 2025 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 425.0% in 2024, then crashed 63.53% in 2025.
- Inhibrx Biosciences' Accumulated Depreciation & Amortization stood at $1.2 million in 2023, then soared by 91.86% to $2.3 million in 2024, then plummeted by 74.53% to $582000.0 in 2025.
- Per Business Quant, the three most recent readings for INBX's Accumulated Depreciation & Amortization are $582000.0 (Q3 2025), $662000.0 (Q2 2025), and $675000.0 (Q1 2025).